Frontline Treatment of CD30+Peripheral T-Cell Lymphomas with Brentuximab Vedotin in Combination with CHP: 3-Year Durability and Survival Follow-up Horwitz, S. M., Shustov, A. R., Forero-Torres, A., Bartlett, N. L., Advani, R., Pro, B., Chen, R., Davies, A. J., Illidge, T., Huebner, D., Kennedy, D. A., Fanale, M. A. AMER SOC HEMATOLOGY. 2015

View details for Web of Science ID 000368019005015